Skip to main content
. 2010 Jul 5;29(36):5032–5047. doi: 10.1038/onc.2010.250

Figure 3.

Figure 3

ARRDC3 negatively regulates in vivo tumorgenicity. Stable cells lines of MDA-MB-231 cells were injected into the mammary fat pads of immunocompromised mice (n=20 injections for each cell line) and grown for 7 weeks. (a–b) Overexpression of ARRDC3 (ARRDC3) led to a decrease in in vivo tumor size compared with vector control (Flag), whereas repression of ARRDC3 (shARRDC3) led to an increase in tumor size compared with control (shCtl). (c) When quantified, the differences in final tumor volume were statistically significant compared with scrambled short hairpin RNA and empty vector controls. (d) ARRDC3 affects the in vivo proliferation of tumor cells as determined by percentage of Ki67-positive cells. Xenograft tumor sections were analyzed for Ki67 using IHC. Over 1500 cells per tumor were counted and scored either Ki67+ or Ki67−. In all, four to five tumor samples per group were analyzed and data bars represent mean±s.e.m. Single asterisk represents P<0.05, whereas a double asterisk represents P<0.001 as determined by Student's t-test.